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Introduction
Bacterial infections commonly overwhelm host defenses and 
require antimicrobial therapy. For over twenty years and despite 
newer alternative antibiotics, aminoglycosides remain the 
mainstay treatment worldwide for numerous disease entities, 
including pneumonia, peritonitis, sepsis, and genitourinary tract 
infection (1, 2). The salient features of aminoglycosides include 
potent antimicrobial activities and minimal drug-related aller-
gies. On the other hand, their major limiting side effects are 
nephrotoxicity, loss of vestibular function, and permanent 
hearing impairment, which is detected in approximately 20% 
of treated patients using conventional audiometry (3, 4). When 
higher frequency hearing is examined, hearing loss is found in 
almost half of treated patients (47%) (5). This prevalence may 
be even higher at longer periods after treatment when consid-
ering the prolonged half-life of drug in the inner ear cochlea 
and the irreversible nature of cochlear hair cell loss (6). Despite 
these side effects, the World Health Organization recommends 
aminoglycosides as critically important antimicrobials for clin-
ical use (7). At present, aminoglycoside-induced hearing loss 
represents one of the most common iatrogenic and preventable 
forms of hearing loss.
In both humans and animals, aminoglycosides cause hear-
ing loss by inducing sensory hair cell degeneration (3, 4). The 
drug is first transported across the blood-labyrinth barrier to 
enter the endolymph-filled inner ear compartments (8). It then 
traverses the mechanotransducer channels or other cation 
channels to enter hair cells (9–11), resulting in cell demise most 
likely as a result of the generation of reactive oxygen species (3, 
12). Past efforts to neutralize aminoglycoside ototoxicity have 
emphasized the administration of antioxidants, yet the efficacy 
of this approach is limited (4, 13–15), in part because of the long 
half-life of aminoglycosides once they enter hair cells (6).
Alternatively, recent studies suggest that structural dif-
ferences of the aminoglycoside compounds may contribute 
to differential ototoxicity (16, 17). In particular, apramycin, 
an aminoglycoside used in veterinary medicine, is less toxic 
to hair cells, and its diminished toxicity is correlated with its 
lower affinity to eukaryotic ribosomes than bacterial ribosomes 
(16). Although this is a proof of concept that different chem-
ical sites on the aminoglycoside contribute to antimicrobial 
activity and ototoxicity, several aminoglycoside derivatives 
exhibit decreased ototoxicity yet lack antibacterial activity (18). 
Thus, a mechanism to modify aminoglycoside to eliminate 
its ototoxic effects while preserving its antimicrobial effect 
remains elusive.
Inner ear hair cells are mechanoreceptors uniquely equipped 
with mechanotransducer (MET) channels located on their stere-
ociliary bundles (19). Because aminoglycoside transport via the 
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Results
Novel aminoglycoside derivatives exhibit decreased ototoxicity in 
vitro. Electrochemical gradients drive cations through the hair 
cell MET channels (Figure 1A and ref. 24). Although the molecular 
nature of this channel remains controversial, a significant body of 
literature exists on the biophysical properties (24, 26–30). Given 
that aminoglycosides are permeable blockers of the MET chan-
nel, we hypothesized that targeted modification to reduce posi-
tively charged sites on the aminoglycoside molecule would hinder 
drug entry into hair cells and thus prevent ototoxicity (9). Using 
established synthetic methods (31), we first chemically protected 
3 of the amine groups on the aminoglycoside sisomicin, a biosyn-
thetic precursor of gentamicin, thus allowing subsequent modi-
fication of the N1 and/or N3′′ amine site (Supplemental Figure 1, 
A and B; supplemental material available online with this article; 
doi:10.1172/JCI77424DS1). Sisomicin was selected because it is 
hair cell MET channel is required for drug toxicity (9, 20–23), 
we have redesigned and modified the aminoglycoside sisomicin 
based on the biophysical properties of the hair cell MET chan-
nels (24) and aminoglycoside-bacterial ribosome interactions 
(25). Here, we have characterized 9 sisomicin derivatives with 
diminished ototoxicity in vitro, with 3 of the 9 compounds exhib-
iting comparable anti–E. coli activities to the parent compound 
sisomicin. The lead compound, N1MS, showed reduced perme-
ation of the MET channel, likely due to the reduced charge per 
molecule of N1MS. In a mouse model of aminoglycoside-in-
duced deafness, N1MS was significantly less ototoxic than 
sisomicin. Finally, N1MS treatment eliminated urinary tract 
infection in vivo. Collectively, our study characterizes a novel 
nonototoxic aminoglycoside and also introduces an approach to 
modifying existing aminoglycosides that can reduce ototoxicity 
while retaining antimicrobial activity.
Figure 1. Novel aminoglycosides have diminished ototoxicity in vitro. (A) Schematic showing that the nonselective hair cell MET channels are perme-
able to cations (calcium and aminoglycosides). (B) The sisomicin compound is comprised of 3 rings. Targeted modifications were made to the amine 
groups on the second (N1) and third rings (N3”). Three distinct chemical moieties were used to modify sisomicin: MS, PS, and BZ. N1BZ: R1=BZ, R2=H; 
N1MS: R1=MS, R2=H; N1PS: R1=PS, R2=H; N1,3”BZ: R1=BZ, R2=BZ; N1,3”MS: R1=MS, R2=MS; N1,3”PS: R1=PS, R2=PS; N3”BZ: R1=H, R2=BZ; N3”MS: 
R1=H, R2=MS; N3”PS: R1=H, R2=PS. (C) Experimental paradigm using cochleae from P4 rats to assess ototoxicity of sisomicin and its derivatives in 
vitro. AG, aminoglycoside. (D) Representative micrograph of the basal turn of undamaged, cultured cochleae, showing myosin VIIa–expressing outer 
and inner hair cells (OHC and IHC). (E) Sisomicin-treated (200 μM) cochleae showing dramatic loss of outer hair cells. (F) Hair cells were preserved in 
cochleae cultured with N1MS (200 μM). (G) Hair cell survival (normalized to undamaged, cultured cochleae) in cochleae (divided into 3 regions [base, 
middle, and apex]) treated with sisomicin or its derivatives (all 200 μM). Sisomicin caused a basal-apical gradient of hair cell loss, whereas treatment 
with each of the 9 sisomicin derivatives caused less hair cell loss. (H) Dose-response analyses comparing dosage of sisomicin and N1MS treatment to 
hair cell loss in the basal turn of the cochlea. Sigmoidal best fits estimated KDs of sisomicin and N1MS to be 100 μM and 1.7 mM, respectively. Data are 
shown as average ± SEM. n = 4–10 for G and H. Scale bar: 25 μm.
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strains (9 of 10), including all 3 extended spectrum β lactamase–
producing (ESBL-producing) strains (Figure 3A), which are mul-
tidrug resistant and known to be associated with high rates of 
patient mortality (35, 36). N1MS inhibited 8 of 10 K. pneumoniae 
strains (including 3 of 5 ESBL producers), whereas sisomicin was 
active against 6 of 10 strains (1 of 5 ESBL producers; Figure 3B). 
Compared with sisomicin, N1MS showed diminished activities 
against P. aeruginosa and S. aureus strains (P < 0.05 for both; Fig-
ure 3, C and D). While modifying the 3′′ amine group abolished 
antibacterial activities of all 6 sisomicin derivatives (Figure 2), 
3 of 6 (N3′′PS, N1,3′′PS, N1,3′′BZ) compounds retained some 
ototoxic effects (Supplemental Figure 3). Conversely, modifying 
the 1 amine alone reduced the spectrum of antibacterial effects; 
enhanced activity against E. coli and K. pneumoniae, particu-
larly against ESBL producers (Figure 3, A and B); and effectively 
diminished ototoxicity. Together, our results indicate that chem-
ical modification of sisomicin can dissociate its ototoxicity from 
antimicrobial activities against E. coli and K. pneumoniae, con-
sistent with previous results on the aminoglycoside apramycin 
(16). However, the findings that N1MS showed decreased toxic-
ity against hair cells (17 times less ototoxic), P. aeruginosa spe-
cies (22 times less ototoxic), and S. aureus species (18 times less 
ototoxic) suggest that such dissociation may be species specific. 
Whether loss of antibacterial activity results from decreased 
entry into bacteria (2) and/or diminished interaction with bacte-
rial ribosomes remains to be determined.
Novel aminoglycoside shows diminished entry via hair cell MET 
channels. Aminoglycosides are permeant blockers of the hair cell 
MET channels (10, 24, 27). To assess aminoglycoside trafficking 
across MET channels, electrophysiological measurements of rat 
cochlear hair cells were performed in vitro. As expected, sisomicin 
(100 μM) reduced inward currents elicited by mechanical stimu-
lation (Figure 4A). In comparison, current amplitudes in the pres-
ence of an identical concentration of N1MS were larger, indicating 
that N1MS acted as a lower affinity blocker for the MET channels 
than sisomicin.
Furthermore, voltage clamping of hair cells showed decreased 
inward and outward currents in the presence of sisomicin or N1MS 
across all voltages tested (Figure 4, A and B). The nonlinear volt-
age-current relationships after drug treatment (sisomicin or N1MS) 
suggest that both drugs acted as permeant blockers, whose abil-
ity to reduce MET channel currents (and thus block the channel) 
was diminished at the most negative and positive holding poten-
tials. Dose-response experiments at a holding potential of –80 mV 
commercially available at high purity (>98%) as compared with 
gentamicin. We selected 3 moieties (methylsulfonyl [MS], phenyl-
sulfonyl [PS], and benzoyl [BZ]) to modify these 2 amine groups 
(1 and 3′′) (Figure 1B and Supplemental Figure 1B), which were 
predicted by X-ray crystallography as dispensable sites for the 
bacterial ribosome binding-dependent antimicrobial effects of 
aminoglycosides (25). These functional groups were conjugated to 
the 1 amine group (N1MS, N1PS, N1BZ), 3′′ amine group (N3′′MS, 
N3′′PS, N3′′BZ), or both the 1 and 3′′ amine groups (N1,3′′MS, 
N1,3′′PS, N1,3′′BZ) of sisomicin (Figure 1B, Supplemental Figure 
1C, and Supplemental Figure 2). The chemical synthetic schemes 
are detailed in Supplemental Figure 1 and ref. 32).
Like gentamicin, sisomicin (200 μM for 1 hour) caused a 
basal-apical gradient of hair cell loss in in rat cochlear cultures 
(Figure 1, C–H, and Supplemental Table 1). At the molar equivalent 
of the parent compound sisomicin (200 μM), all 9 new sisomicin 
derivatives induced markedly less hair cell loss, with 4 compounds 
showing almost no hair cell toxicity (Figure 1G and Supplemen-
tal Table 1). Conjugation with the MS moiety was more effective 
than that with either the PS or BZ structures in ameliorating oto-
toxicity (Supplemental Figure 3, A–C), and all 3 modifications of 
the sisomicin backbone with the MS moiety eliminated ototoxicity 
(Supplemental Figure 3, D–F). Dose-response experiments (drug 
exposure for 1 hour, as above) showed that N1MS (>95% pure, 
Supplemental Figure 2) is 17 times less toxic than sisomicin (98% 
pure, KD = 100 ± 2 μM and 1.7 ± 0.2 mM, respectively; Figure 1H 
and Supplemental Table 2). These data suggest that specific mod-
ification of aminoglycosides effectively reduced toxicity against 
hair cells in vitro.
Novel aminoglycoside derivatives show antibacterial activities 
in vitro. Enterobacteriaceae rank among the most frequently iso-
lated organisms from patients (33). Based on this, we next tested 
the antimicrobial activities of sisomicin and its derivatives against 
E. coli in vitro. Sisomicin and 2 sisomicin derivatives (N1MS and 
N1PS) showed comparable minimal inhibitory and bactericidal 
concentrations (using a concentration of <4 μg/ml to define anti-
microbial activity; ref. 34 and Figure 2). All 6 compounds modi-
fied at the 3′′ amine site showed diminished antimicrobial effects 
(N3′′MS, N3′′PS, N3′′BZ, N1,3′′MS, N1,3′′PS, N1,3′′BZ; Figure 2).
Because N1MS displayed the most favorable antibacterial 
activity-ototoxicity profile, it was further tested against clinical 
isolates of E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
and Staphylococcus aureus. Similar to sisomicin, gentamicin, and 
tobramycin, N1MS effectively suppressed growth of most E. coli 
Figure 2. Sisomicin and its novel derivatives exhibit anti-
bacterial activities. The MICs and MBCs of sisomicin and 9 
derivatives were quantified. Using 4 μg/ml (drawn as dotted 
line) as the criteria set forth by the Clinical and Laboratory 
Standards Institute, we found that sisomicin, N1MS, and 
N1PS robustly inhibited growth of and killed E. coli. Data are 
shown as average ± SEM. n = 5.
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tion product otoacoustic emissions (DPOAEs) 1 and 5–6 weeks 
later (Figure 5, C, E, and F). In contrast, we detected no signifi-
cant threshold shifts in ABR and DPOAE measurements, except 
a shift from 8 to 17 dB at the 2 highest frequencies, 1 and 5–6 
weeks after N1MS treatment (Figure 5, D–F).
Surface preparation of cochleae from sisomicin-treated 
mice displayed extensive outer hair cell loss in the middle and 
basal turns (16.9% ± 10.1% and 11.1% ± 10.5% of saline-treated 
controls, P < 0.001 for both; n = 9 mice; Figure 6, A and B, 
and Supplemental Table 3), corresponding to loss of auditory 
function in those animals. Conversely, cochleae from N1MS-
treated animals showed substantially more hair cells than 
sisomicin-treated animals, and thus less toxicity, 1 week and 
5–6 weeks after treatment (Supplemental Table 3), consistent 
with their auditory measurements, which were comparable to 
those of saline-injected animals (Figure 5, E and F).
To rule out collateral toxicity by sisomicin and N1MS 
outside the auditory system, 35 different types of organs were 
examined 3 days after drug administration. Among 5 sisomi-
cin-treated animals, acute renal tubular epithelial degenera-
tion was detected in 2 animals, whereas no tissue toxicity was 
detected in any of the 10 N1MS-treated animals (Supplemental 
Table 4). Moreover, we performed dose-response experiments 
in vivo to determine drug doses that induced animal death and 
found that sisomicin was lethal at lower doses than N1MS (LD50: 
200 ± 2 mg/kg and 544 ± 7 mg/kg, respectively; Supplemental 
Figure 4). Based on this, we tested the effects of a higher sub-
lethal dose of N1MS and combined it with loop diuretic chal-
lenge (400 mg/kg N1MS and 300 mg/kg furosemide). While 
sisomicin caused ~100% animal mortality at this dose, >95% 
N1MS-treated animals survived for over a month under these 
conditions. After treatment with N1MS at this higher dose, 
there were marked ABR and DPOAE threshold shifts with cor-
showed that drug concentrations blocking 50% of MET channel 
currents were lower for sisomicin than N1MS (KD = 65.0 ± 17.7 and 
96.1 ± 9.9 μM, respectively) (Figure 4C). Likewise, at the other neg-
ative holding potentials examined, the KD for sisomicin was sig-
nificantly lower than that for N1MS (P < 0.0001, 1-way analysis of 
covariance; Figure 4D). Taken together and considering that N1MS 
is less positively charged than sisomicin, these data indicate that 
N1MS is less likely to traverse the hair cell MET channel and thus 
enter hair cells than the parent compound sisomicin.
Novel aminoglycosides prevent hair cell loss and hearing loss in vivo. 
To compare the ototoxicity of sisomicin and N1MS in vivo, we tested 
them in a deafness paradigm in mice (37). By challenging 30-day-old 
normal hearing CBA/CaJ mice with a combination of sisomicin and 
a loop diuretic (single injection of 175 mg/kg sisomicin followed by 
300 mg/kg furosemide; Figure 5A), we induced substantially ele-
vated thresholds in auditory brainstem responses (ABRs) and distor-
Figure 3. Sisomicin and its novel derivatives inhibit growth of 
different bacterial species. (A) Minimal inhibitory concentrations 
for N1MS, sisomicin, gentamicin, and tobramycin against 10 clinical 
isolates of E. coli showed that all 4 compounds inhibited growth of 
most strains. Asterisks indicate ESBL-producing strains. MIC50 and 
MIC90: sisomicin = 1 and >32 μg/ml; N1MS = 2 and 4 μg/ml;  
gentamicin = 0.5 and >32 μg/ml; tobramycin = 1 and 4 μg/ml, 
respectively. (B) Growth of most K. pneumoniae strains, including 
some ESBL-producing ones (asterisks), were inhibited by N1MS, 
whereas sisomicin, gentamicin, and tobramycin showed robust 
activities predominantly against non-ESBL-producing strains. MIC50 
and MIC90: sisomicin = 1 and >32 μg/ml; N1MS = 1 and 128 μg/ml; 
gentamicin = 0.5 and 64 μg/ml; tobramycin = 0.5 and 32 μg/ml, 
respectively. (C) Sisomicin, gentamicin, and tobramycin inhibited 
growth of most P. aeruginosa strains, including drug-resistant 
strains (asterisks). N9744 is resistant to ciprofloxacin, N9750 is 
resistant to imipenem, and N9923 and N9749 are multidrug resis-
tant. N1MS was inactive against most P. aeruginosa strains. MIC50 
and MIC90: sisomicin = 0.5 and 8 μg/ml; N1MS = 16 and 64 μg/ml;  
gentamicin = 2 and 16 μg/ml; tobramycin = 0.5 and 4 μg/ml, respec-
tively. (D) Growth of most S. aureus strains was suppressed by siso-
micin, gentamicin, and tobramycin but not N1MS treatment. Asterisks 
indicate methicillin resistant strains. MIC50 and MIC90: sisomicin = 0.25 
and 0.25 μg/ml; N1MS = 8 and 8 μg/ml; gentamicin = 0.5 and  
0.5 μg/ml; tobramycin = 0.5 and 0.5 μg/ml, respectively. Each bar 
represents one experiment (n = 1).
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25-g animal) effectively suppressed bacteriuria (Figure 7, B–D). 
Moreover, bladder and kidney homogenates collected on day 6 
demonstrated that both sisomicin and N1MS reduced bacterial 
titers in urinary tract issues (Figure 7, E and F). One week after 
treatment, N1MS- and sisomicin-treated mice exhibited normal 
ABR and DPOAE waveforms and thresholds and also normal 
serum creatinine levels (625 μg for both; Supplemental Figure 
5). In summary, these results indicate that N1MS is effective at 
eliminating E. coli–mediated urinary tract infection, without 
compromising auditory and kidney functions.
Discussion
Aminoglycosides are potent antibiotics that are actively used 
worldwide, with ototoxicity being the major dose-limiting side 
effect. Our study uses a novel chemical synthetic approach for 
alleviating aminoglycoside ototoxicity while preserving anti-
responding hair cell degeneration (Figure 5, E and F, and Sup-
plemental Table 3). These in vivo data indicate that the sisomi-
cin derivative N1MS is substantially less toxic than sisomicin, 
corroborating the in vitro findings that modification of amino-
glycosides markedly reduced their ototoxicity.
Novel aminoglycosides eradicate urinary tract infection. E. coli 
is the most common pathogen causing urinary tract infections 
(38). To test whether N1MS is effective against urinary tract 
infections, we inoculated mouse urinary tracts with a uropatho-
genic strain of E. coli (39) followed by treatment with 5 sequen-
tial injections of sisomicin or N1MS (Figure 7A). In comparison 
with saline-injected controls, from which serially collected 
urine consistently yielded high titers of E. coli, both sisomicin 
and N1MS effectively eliminated bacteria from urine collected 
1, 4, and 6 days after inoculation (Figure 7, B–D). All 3 con-
centrations of N1MS (25, 125, and 625 μg at 5 doses per 20- to 
Figure 4. Hair cell MET responses at different membrane holding potentials after sisomicin and N1MS treatment. (A and B) Mechanical stimulation (a 
negative step of 650 nm for 0.1 ms, then a positive step of 650 nm for 5 ms) was used to stimulate hair cell hair bundles at different membrane holding 
potentials (stepped from –180 to +120 in 20-mV increments). Responses to mechanical stimuli were obtained at different holding potentials to generate 
the current responses shown in the absence and presence of sisomicin (red) or N1MS (blue, both at 100 μM). Sisomicin reduced current amplitudes more 
effectively than N1MS and thus acts as a higher affinity blocker for the MET channel. Current-voltage plots show that sisomicin reduced both inward (at 
negative potentials) and outward currents (at positive potentials) and displayed loss of block at both extreme negative and positive steps, indicating that 
sisomicin acts as a permeant blocker of the MET channel. Measurements under identical conditions found that blockage with N1MS was markedly dimin-
ished. (C) Remaining fraction of control current for sisomicin and N1MS at a holding potential of –120 mV at different concentrations (10, 30, 100, 300, and 
1,000 μM). (D) KD derived from remaining control current fraction for sisomicin and N1MS at different holding potentials and concentrations (–180 to +120, 
20-mV increments). Data are shown as average ± SD. n = 2–9.
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bacterial activity. We modified the aminoglycoside compound 
based on the notion that hindering aminoglycoside entry via 
hair cell MET channel prevents ototoxicity (9, 20). The design 
was based on the biophysical properties of the MET channel 
(24, 26), whose candidate molecular compositions are still 
being elucidated (22, 40–42). Nonetheless, electrochemical 
gradients drive cations through the MET channel; therefore, 
the conversion of basic amine sites of aminoglycosides into car-
boxamides or sulfonamides renders them nonbasic (less posi-
tively charged) and was predicted to decrease drug entry and 
subsequent toxicity. Our paradigm produced sisomicin deriva-
tives exhibiting diminished in vitro toxicity relative to the par-
ent compound sisomicin, with the lead compound N1MS less 
capable of crossing the MET channels than sisomicin. While 
the electrophysiological measurements were made in vitro to 
assess drug entry across the MET channel, the electrochemi-
cal gradient present in vivo in the intact cochlea is substan-
tially larger. This difference may in part account for the 17-fold 
decreased ototoxicity in vitro and 2.3-fold decreased ototoxic-
ity in vivo between N1MS and sisomicin. As the MET channel 
pore size is estimated at 1.25 ± 0.08 nm at its narrowest seg-
ment (24), it is possible that the larger sizes of sisomicin deriva-
tives may have also impeded drug entry. However, the effects of 
compound dimension are likely limited, as the moieties added 
were relatively small. Thus, future experiments using bulkier 
moieties may further delineate the relationships among amino-
glycoside dimensions and drug entry and ototoxicity.
A rich body of literature supports the hypothesis that oxida-
tive stress mediates aminoglycoside-induced hair cell degenera-
tion (12, 43), yet the initial events that generate reactive oxygen 
species are poorly understood. Building upon the knowledge that 
the human mitochondrial mutation A1555G (GenBank accession 
no. NC 012920) increases the risk of hearing loss after aminogly-
coside treatment (44), recent work has revealed the potential roles 
of mitochondrial stress in aminoglycoside ototoxicity (16, 45). In 
particular, work on apramycin, a structurally unique aminogly-
coside used in veterinary medicine, suggests that its differential 
antiribosomal activities against eukaryotic cells versus bacteria 
contribute to its low ototoxic potential. Moreover, recent work 
suggests that aminoglycosides induce hair cell toxicity by causing 
ribotoxic stress and in turn inhibit cytoplasmic protein synthesis 
(46). While our data support the conclusion that decreased drug 
entry via MET channels underlies diminished aminoglycoside 
ototoxicity, we did not determine whether sisomicin and sisomi-
cin derivatives differentially bind eukaryotic and bacterial ribo-
somes, induce ribotoxic stress, or inhibit protein synthesis in hair 
cells. One or all of these mechanisms may have also contributed to 
N1MS’s decreased ototoxicity.
Because aminoglycosides can provide broad coverage of 
gram-negative organisms, they are widely used when the offending 
organisms are unknown, such as in the setting of neonatal sepsis or 
peritonitis (47, 48). Additionally, aminoglycosides are clinically indi-
cated for treating pneumonia caused by P. aeruginosa and urinary 
tract infection caused by E. coli (2). Differential binding affinities for 
Figure 5. Modified aminoglycoside prevents hearing loss. (A) Schematic of drug treatment to deafen 30-day-old CBA/CaJ mice. (B) Representative ABR 
tracings in a saline-treated mice showing a 30 dB SPL threshold at 23 kHz. (C) Sisomicin-treated (175 mg/kg) mice showed no detectable responses. (D) 
In contrast, mice administered with N1MS (175 mg/kg) exhibited normal auditory responses (thresholds = 30 dB SPL). (E and F) ABRs and DPOAEs of 
animals administered saline 1 week prior (magenta), 175 mg/kg sisomicin 1 week prior (black), 175 mg/kg N1MS 1 week prior (red), 175 mg/kg sisomicin 
5–6 weeks prior (green), 175 mg/kg N1MS 5 to 6 weeks prior (blue), and 400 mg/kg N1MS 1 week prior (cyan). Sisomicin-treated animals had elevated 
ABR and DPOAE thresholds in comparison to saline-treated animals, whereas N1MS-treated animals had robust ABR and DPOAE signals 1 and 5–6 
weeks after treatment. High-dose sisomicin treatment was lethal (Supplemental Figure 5). High-dose N1MS treatment caused elevated ABR and DPOAE 
thresholds. Data are shown as average ± SEM. For E and F, n = 57 for saline control; n = 9–14 for other groups. 
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bacterial ribosomes may contribute to the selectivity of individual 
aminoglycosides (49, 50). The findings that modification at the 3′′ 
amine site reduced antibacterial activity and that N1MS is selectively 
active against E. coli and K. pneumoniae are consistent with such a 
structure-activity relationship. Although N1MS shows decreased 
activity against P. aeruginosa and S. aureus, it is conceivable that 
a higher dose of the less ototoxic N1MS may be used to overcome 
its diminished antimicrobial activity against these organisms. The 
effects on nephrotoxicity of such a regimen will need to be eluci-
dated. Alternatively, modifications at the 1 amine site may further 
separate ototoxicity from antimicrobial activity and restore efficacy 
against a wide spectrum of bacteria. Thus, future studies should fur-
ther delineate N1MS’s therapeutic window and the structural activ-
ity relationships of additional aminoglycoside derivatives.
Aminoglycoside-induced vestibulotoxicity presents both as a 
side effect of treatment for systemic infection (4) and as an intended 
therapeutic effect, such as for Meniere’s disease (51). However, the 
current study did not directly compare whether sisomicin and its 
derivatives differ in their vestibular hair cell toxicity; such a compar-
ison may help determine the candidacy of aminoglycoside deriva-
tives as clinical therapeutics.
As ototoxicity limits both the dose and duration of aminogly-
coside treatment, our study provides proof-of-concept data sup-
porting targeted modification of aminoglycosides as an effective 
strategy to prevent iatrogenic hearing loss. Future studies modify-
ing other aminoglycoside compounds may help generate a family 
of aminoglycoside antibiotics with minimized risk of ototoxicity 
and thus add to the armamentarium of antibiotics.
Methods
Cochlear cultures. Cochlear tissues were harvested from P4 rats 
and cultured as previously described (9). Sterile dissection was 
first performed in Hank’s balanced salt solution or Leibovitz’s L-15 
medium (GIBCO, Life Technologies Corp.). Harvested tissues were 
cultured in Dulbecco’s Modified Eagle Medium/F-12 medium con-
taining 10% heat-inactivated fetal bovine serum (both GIBCO) and 
0.01% ampicillin (Sigma-Aldrich) overnight (37°C and 5% CO2) 
before aminoglycoside treatment. Drug treatment lasted 1 hour, 
after which organs were incubated in aminoglycoside-free media 
for an additional 48 hours. Sisomicin sulfate (98% pure, OChem), 
gentamicin, and tobramycin were used (Sigma-Aldrich). Sisomicin 
derivatives were synthesized by Nanosyn Inc. (see below).
Chemical synthesis. The modified sisomicin derivatives were 
prepared from sisomicin sulfate, which was first converted into 
N-6′-p-nitrobenzyloxycarbonyl-N-2′,N-3-bis-t-butyloxycarbonyl 
sisomicin using published procedures (refs. 31, 32, and Supple-
mental Figure 1A). Because N1 has been demonstrated to react 
preferentially over N3′′ with acid chlorides (31), sulfonylation or 
benzoylation occurs selectively at the N1 amine, while both N1 
and N3′′ are functionalized with the use of excess reagent (Sup-
plemental Figure 1A). For the monofunctionalization of N3′′, 
N-6′-p-nitrobenzyloxycarbonyl-N-2′,N-3-bis-t-butyloxycarbonyl 
sisomicin was further protected as the N-1 o-nitro benzene sulfonyl 
derivative (Supplemental Figure 1B), followed by sulfonylation 
or benzoylation of N3′′. Last, deprotection of the functionalized 
molecules was done using established procedures (31, 52). The 
final products were purified by preparative high-pressure liquid 
chromatography (not shown), with their purities determined by 
mass spectrometry (evaporative light scattering detector) (N1BZ = 
100%, N1MS = 99.0%, N1PS = 96.4%, N1,3′′BZ = 99.0%, N1,3′′MS = 
99.5%, N1,3′′PS = 98.9%, N3′′BZ = 99.3%, N3′′MS = 99.0%, and 
N3′′PS = 99.3%). The structural assignments were also confirmed 
using a Thermo Ultimate 3000 RS UHPLC system.
Electrophysiology. P7–9 rat cochlear explants were prepared and 
whole cell patch recordings were obtained from inner hair cells as 
previously described (19, 53). The pipette solution contained 125 mM 
CsCl, 3.5 mM MgCl2, 5 mM ATP, 5 mM creatine phosphate, 10 mM 
HEPES, 1 mM EGTA, 2 mM ascorbate (pH = 7.2), 280–285 mOsm 
per kg water, while the extracellular solution contained 140 mM 
NaCl, 2 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 6 mM 
glucose, 2 mM pyruvate, 2 mM ascorbate (pH = 7.4), 300–310 mOsm 
per kg water. A glass probe affixed to a piezoelectric stack was used 
to mechanically stimulate the hair bundles; stimulus amplitudes were 
selected to provide the maximal positive and negative response.
Immunohistochemistry. As previously described (9), cultured tis-
sues were fixed with 4% paraformaldehyde in PBS at pH 7.4 for 20 
minutes at room temperature. For adult cochlear tissues, fixative was 
gently infused through an apical bony window and the oval window 
and then incubated in fixative for 45 minutes at room temperature. 
EDTA was applied to tissues (500 mM for 30 to 40 minutes), before 
washing with PBS 3 times. Bony capsules of cochleae were micro-
dissected away, and stria vascularis and tectorial membranes were 
removed to expose the organ of Corti.
Tissues were then immersed in a blocking solution containing 5% 
bovine serum albumin and Triton-X 1% in PBS for 1 hour. Samples were 
incubated with anti–myosin VIIa antibody (1:1,000; Proteus Biosci-
Figure 6. Modified aminoglycoside prevents sensory cell loss in vivo. (A) 
Whole-mount preparation showing myosin VIIa–positive hair cells in the 
cochlear basal turn. Three rows of outer hair cells and a single row of inner hair 
cells are present in saline-treated animals. (B) Sisomicin treatment caused outer 
hair cell loss. (C) Hair cells are preserved in N1MS-treated animals. (D) Quan-
tification of myosin VIIa–positive outer hair cells shows dramatic cell loss (as 
percentages of saline-treated controls) in a basal-apical gradient after sisomicin 
treatment, whereas N1MS treatment preserved markedly more hair cells. Treat-
ment with 400 mg/kg N1MS produced hair cell loss. Data are shown as average ± 
SEM. For D, n = 57 for saline control; n = 9–14 for other groups. Scale bar: 25 μm.
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To determine the minimum bactericidal concentration (MBC) of 
the aminoglycoside compounds, we streaked out 50 μl from aminogly-
coside-containing, bacteria-inoculated tubes that exhibited no bacte-
rial growth during MIC assays onto Müller-Hinton agar (Becton Dick-
erson) and incubated them overnight at 37°C. Lack of bacterial growth 
was used to confirm the MBC for each aminoglycoside compound.
For testing against other bacterial strains, sisomicin and deriv-
atives were sent to the Clinical Microbiology Institute, where MIC’s 
were determined using the above methods.
Mouse model of urinary tract infection. Procedures were performed 
as previously described (39). Briefly, type I pili expression was induced 
in the uropathogenic E. coli strain UTI89 by inoculating bacteria into 
5 ml Luria-Bertani broth, followed by growth at 37°C overnight to reach 
static phase. Bacteria were then subcultured 1:100 into 5 ml fresh media, 
followed by growth at 37°C for another 18 hours to reach static phase 
again. These cultures were centrifuged for 10 minutes at 13,000 g, 
resuspended in 2 ml PBS, and then diluted to approximately 2 × 108 
CFU per ml. Fifty μl of this suspension (107 CFU) was inoculated into 
the bladders of female 7- to 8-week-old CBA/CaJ mice by transurethral 
catheterization. For drug treatment, infected mice were injected subcu-
taneously with sisomicin or N1MS (25–625 μg/25 g dissolved in 100 μl 
of PBS) every 2 hours for a total of 5 injections after UTI89 infection.
Aseptically excised bladders and kidneys were minced and homoge-
nized in 400 μl sterile PBS. Freshly collected urine or tissue homogenates 
were then serially diluted 10- to 1,000-fold. Twenty-five μl of each dilu-
tion was plated onto MacConkey agar plates. CFUs were counted after 
ences) in blocking solution overnight at 4°C. The following day, tissues 
were rinsed with PBS and incubated with a fluorescent secondary anti-
body (Alexa Fluor 555 goat anti-rabbit, 1:800; Invitrogen, Life Technol-
ogies Corp.) in blocking solution for 1 hour. A subset of tissues was also 
immersed in phalloidin (Alexa Fluor Phalloidin, 1:1,000; Invitrogen) 
diluted in blocking solution for 30 minutes. Finally, tissues were rinsed 
with PBS before being mounted in ProLong Gold Antifade Reagent 
(Invitrogen) and coverslipped for further imaging and analysis.
Microscopic imaging and quantification. Tissues were imaged using 
a confocal laser scanning microscope (Zeiss LSM 5 Pascal AxioVert 
200M, Carl Zeiss AG). The cochlea was divided into 3 regions (base, 
middle, and apex), and 1 or 2 areas per region were imaged. In every 
area, outer hair cells were counted.
Bacterial culture. Antimicrobial activity was measured by incubat-
ing serial dilutions of sisomicin or derivatives with a constant bacterial 
inoculum. E. coli XL blue (Agilent Technologies) was incubated in 3 ml 
Müller-Hinton broth (Becton Dickerson) at 37°C overnight to generate 
static phase cultures. The following day, incubation tubes were inoculated 
with 106 CFU bacteria. Serial 2-fold dilutions of the aminoglycoside com-
pounds (0.03–64 μg/ml) were added to 2 ml Müller-Hinton broth (54). 
The inoculated tubes were incubated at 37°C overnight. The lowest anti-
biotic concentration sufficient to inhibit bacterial growth (an absence of 
a bacterial pellet at the bottom of the tube) was defined as the minimum 
inhibitory concentration (MIC). To determine antibiotic efficacy, we used 
an antibiotic concentration of <4 μg/ml as the criteria, as defined for gen-
tamicin by the Clinical and Laboratory Standards Institute (34).
Figure 7. N1MS eradicates 
urinary tract infection in vivo. 
(A) Schematic of E. coli infection 
of the mouse urinary tract and 
treatment with sisomicin or 
N1MS. The uropathogenic  
E. coli strain UTI89 was inoc-
ulated into bladders of 7- to 
8-week-old CBA/CaJ mice. (B–D) 
Scatter plots show that when 
animals received no antibiotic 
treatment (Abx) (black), urine 
collected on day 1, 4, or 6 fea-
tured high bacterial titers. While 
low doses (25 and 125 μg) of 
sisomicin (red) and N1MS (green) 
reduced bacterial growth, high 
doses of both drugs (625 μg) 
effectively prevented bacterial 
growth. (E and F) Homogenates 
of bladders and kidneys from 
mice whose bladders were inocu-
lated with E. coli were examined 
for bacterial growth. Whereas 
tissues feature high bacterial 
titers in the absence of antibiotic 
treatment, both sisomicin and 
N1MS reduced colony formation, 
especially at the higher doses.  
n = 10 for B–F.
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Statistics. Data were analyzed using Microsoft Excel (Microsoft), 
GraphPad Prism, and Origin softwares (OriginLab). Two-tailed Stu-
dent’s t tests and analysis of covariance were performed. When mul-
tiple t tests were performed, Bonferroni correction was included. 
P < 0.05 was considered statistically significant.
Study approval. Sprague Dawley rats (Charles River Laboratories) 
and CBA/CaJ mice (The Jackson Laboratory) were used. Animal care 
and all experimental procedures were carried out in accordance with 
institutional guidelines at Stanford University.
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overnight incubation at 37°C. The limits of detection were 4,000 CFU/ml 
for urine and 160 CFU per bladder. To determine creatinine levels, 25 μl 
of serum was collected from each mouse and sent to the Diagnostic Labo-
ratory of Veterinary Service Center at Stanford University.
Auditory measurements. ABRs and DPOAEs were measured as pre-
viously described with custom hardware based around a data acqui-
sition board (PCOe-6251, National Instruments) driven by software 
written in MATLAB (Mathworks) (55, 56). Briefly, mice were sedated 
with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). ABR 
signals were measured from a needle electrode positioned inferior to 
the tympanic bulla, referenced to an electrode placed at the vertex 
of the head, and a ground electrode was placed at the hind leg. Tone 
burst stimuli were delivered with frequencies ranging from 4 to 64 
kHz (4, 8, 16, 32, 64 kHz) and sound intensities raised from 10 to 80 dB 
sound pressure level (SPL) in 10-dB steps. At each frequency and 
sound level, 260 trials were sampled and averaged.
DPOAEs were measured by a probe tip microphone in the exter-
nal auditory canal. The sound stimuli were two 1-second sine wave 
tones of differing frequencies (F2 = 1.22 × F1). F2 was varied from 4 
to 46 kHz, and the intensities of 2 tones were from 20 to 80 dB SPL 
with 10-dB steps. The amplitude of the cubic distortion product was 
measured at 2 × F1–F2. The threshold at each frequency was calculated 
to be when the DPOAE was >5 dB SPL and 2 SDs above the noise level. 
For statistical analyses of both ABR and DPOAE responses, a lack of 
response is designated 80 dB SPL.
Histology of organs (necropsy). All procedures were performed by 
a board-certified veterinary pathologist at the Diagnostic Laboratory 
of Veterinary Service Center at Stanford University. First, a complete 
gross examination of organs and tissues was performed. A comprehen-
sive list of organs and tissues was sampled (Supplemental Table 4), and 
then organs and tissues were fixed in 10% neutral buffered formalin. 
After 48 to 72 hours of formalin fixation, the organs and tissues were 
trimmed and processed routinely for light microscopic examination. 
Specifically, 4-micron thick, hematoxylin and eosin–stained tissue sec-
tions were evaluated using an Olympus BX-41 microscope (Olympus).
 1. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici 
L, Paul M. Efficacy and safety of aminoglycoside 
monotherapy: systematic review and meta-anal-
ysis of randomized controlled trials. J Antimicrob 
Chemother. 2007;60(2):247–257.
 2. Becker B, Cooper MA. Aminoglycoside anti-
biotics in the 21st century. ACS Chem Biol. 
2013;8(1):105–115.
 3. Forge A, Schacht J. Aminoglycoside antibiotics. 
Audiol Neurootol. 2000;5(1):3–22.
 4. Huth ME, Ricci AJ, Cheng AG. Mechanisms 
of aminoglycoside ototoxicity and targets 
of hair cell protection. Int J Otolaryngol. 
2011;2011:937861.
 5. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey 
RH, McDonald WJ. High-frequency audiometric 
monitoring for early detection of aminoglycoside 
ototoxicity. J Infect Dis. 1992;165(6):1026–1032.
 6. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of 
gentamicin uptake and release in the rat. Com-
parison of inner ear tissues and fluids with other 
organs. J Clin Invest. 1986;77(5):1492–1500.
 7. World Health Organization. Report of the second 
WHO Expert Meeting, Copenhagen, Denmark. 
Critically important antimicrobials for human 
health. WHO Web site. http://who.int/food-
borne_disease/resistance/antimicrobials_human.
pdf. Accessed December 2, 2014. 
 8. Li H, Steyger PS. Systemic aminoglycosides are 
trafficked via endolymph into cochlear hair cells. 
Sci Rep. 2011;1:159.
 9. Alharazneh A, et al. Functional hair cell 
mechanotransducer channels are required 
for aminoglycoside ototoxicity. PLoS One. 
2011;6(7):e22347.
 10. Marcotti W, van Netten SM, Kros CJ. The amino-
glycoside antibiotic dihydrostreptomycin rap-
idly enters mouse outer hair cells through the 
mechano- electrical transducer channels.  
J Physiol. 2005;567(Pt 2):505–521.
 11. Stepanyan RS, et al. TRPA1-mediated accumulation 
of aminoglycosides in mouse cochlear outer hair 
cells. J Assoc Res Otolaryngol. 2011;12(6):729–740.
 12. Rizzi MD, Hirose K. Aminoglycoside ototox-
icity. Curr Opin Otolaryngol Head Neck Surg. 
2007;15(5):352–357.
 13. Sha SH, Schacht J. Antioxidants attenuate gen-
tamicin-induced free radical formation in vitro 
and ototoxicity in vivo: D-methionine is a poten-
tial protectant. Hear Res. 2000;142(1–2):34–40.
 14. Sha SH, Qiu JH, Schacht J. Aspirin to prevent 
gentamicin-induced hearing loss. N Engl J Med. 
2006;354(17):1856–1857.
 15. Campbell KC, et al. Prevention of noise- and 
drug-induced hearing loss with D-methionine. 
Hear Res. 2007;226(1–2):92–103.
 16. Matt T, et al. Dissociation of antibacterial activity 
and aminoglycoside ototoxicity in the 4-mono-
substituted 2-deoxystreptamine apramycin. Proc 
Natl Acad Sci U S A. 2012;109(27):10984–10989.
 17. Shulman E, et al. Designer aminoglycosides 
that selectively inhibit cytoplasmic rather than 
mitochondrial ribosomes show decreased oto-
toxicity: a strategy for the treatment of genetic 
diseases. J Biol Chem. 2014;289(4):2318–2330.
 18. Nudelman I, Glikin D, Smolkin B, Hainrichson 
M, Belakhov V, Baasov T. Repairing faulty genes 
by aminoglycosides: development of new deriva-
tives of geneticin (G418) with enhanced suppres-
sion of diseases-causing nonsense mutations. 
Bioorg Med Chem. 2010;18(11):3735–3746.
 19. Beurg M, Fettiplace R, Nam JH, Ricci AJ. Local-
Downloaded from http://www.jci.org on April  1, 2015.   http://dx.doi.org/10.1172/JCI77424
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
5 9 2 jci.org   Volume 125   Number 2   February 2015
ization of inner hair cell mechanotransducer 
channels using high-speed calcium imaging. Nat 
Neurosci. 2009;12(5):553–558.
 20. Ou HC, Keating S, Wu P, Simon JA, Raible DW, 
Rubel EW. Quinoline ring derivatives protect 
against aminoglycoside-induced hair cell death 
in the zebrafish lateral line. J Assoc Res Otolaryn-
gol. 2012;13(6):759–770.
 21. Vu AA, et al. Integrity and regeneration of mecha-
notransduction machinery regulate aminogly-
coside entry and sensory cell death. PLoS One. 
2013;8(1):e54794.
 22. Kawashima Y, et al. Mechanotransduction 
in mouse inner ear hair cells requires trans-
membrane channel-like genes. J Clin Invest. 
2011;121(12):4796–4809.
 23. Richardson GP, Forge A, Kros CJ, Fleming J, 
Brown SD, Steel KP. Myosin VIIA is required for 
aminoglycoside accumulation in cochlear hair 
cells. J Neurosci. 1997;17(24):9506–9519.
 24. Farris HE, LeBlanc CL, Goswami J, Ricci AJ. 
Probing the pore of the auditory hair cell 
mechanotransducer channel in turtle. J Physiol. 
2004;558(pt 3):769–792.
 25. Yoshizawa S, Fourmy D, Puglisi JD. Structural 
origins of gentamicin antibiotic action. EMBO J. 
1998;17(22):6437–6448.
 26. Pan B, Waguespack J, Schnee ME, LeBlanc C, 
Ricci AJ. Permeation properties of the hair cell 
mechanotransducer channel provide insight 
into its molecular structure. J Neurophysiol. 
2012;107(9):2408–2420.
 27. Gale JE, Marcotti W, Kennedy HJ, Kros CJ, Rich-
ardson GP. FM1-43 dye behaves as a permeant 
blocker of the hair-cell mechanotransducer 
channel. J Neurosci. 2001;21(18):7013–7025.
 28. Kros CJ, Rusch A, Richardson GP. Mechano- 
electrical transducer currents in hair cells of the 
cultured neonatal mouse cochlea. Proc Biol Sci. 
1992;249(1325):185–193.
 29. Rusch A, Kros CJ, Richardson GP. Block by ami-
loride and its derivatives of mechano-electrical 
transduction in outer hair cells of mouse cochlear 
cultures. J Physiol. 1994;474(1):75–86.
 30. Beurg M, Nam JH, Chen Q, Fettiplace R. 
Calcium balance and mechanotransduc-
tion in rat cochlear hair cells. J Neurophysiol. 
2010;104(1):18–34.
 31. Armstrong ES, Bruss JB, inventors; Achaogen, 
Inc., assignee. Combination therapies using anti-
bacterial aminoglycoside compounds. US patent 
WO2010147836 A1. June 10, 2010.
 32. Ricci AJ, Greenhouse RJ, Cheng AG, inventors; 
The Board of Trustees of the Leland Stanford 
Junior University, assignee. Aminoglycoside 
antibiotics with reduced ototoxicity. US patent 
2014/0274932 A1. March 14, 2014.
 33. Schwaber MJ, Carmeli Y. Mortality and delay in 
effective therapy associated with extended-spec-
trum β-lactamase production in Enterobac-
teriaceae bacteraemia: a systematic review 
and meta-analysis. J Antimicrob Chemother. 
2007;60(5):913–920.
 34. Clinical Laboratory Standards Institute. Perfor-
mance standards for antimicrobial disk and dilu-
tion susceptibility tests for bacteria isolated from 
animals. 3rd ed. Approved Standard M31-A3. 
Wayne, Pennsylvania, USA: CLSI; 2008.
 35. Rodriguez-Bano J, et al. Risk factors and prog-
nosis of nosocomial bloodstream infections 
caused by extended-spectrum-β-lactamase- 
producing Escherichia coli. J Clin Microbiol. 
2010;48(5):1726–1731.
 36. Tumbarello M, et al. Predictors of mortality in 
patients with bloodstream infections caused 
by extended-spectrum-β-lactamase-producing 
Enterobacteriaceae: importance of inadequate 
initial antimicrobial treatment. Antimicrob Agents 
Chemother. 2007;51(6):1987–1994.
 37. Oesterle EC, Campbell S, Taylor RR, Forge A, 
Hume CR. Sox2 and JAGGED1 expression in 
normal and drug-damaged adult mouse inner 
ear. J Assoc Res Otolaryngol. 2008;9(1):65–89.
 38. Ulett GC, Totsika M, Schaale K, Carey AJ, Sweet 
MJ, Schembri MA. Uropathogenic Escherichia 
coli virulence and innate immune responses dur-
ing urinary tract infection. Curr Opin Microbiol. 
2013;16(1):100–107.
 39. Fu CL, Apelo CA, Torres B, Thai KH, Hsieh 
MH. Mouse bladder wall injection. J Vis Exp. 
2011;(53):e2523.
 40. Pan B, et al. TMC1 and TMC2 are components 
of the mechanotransduction channel in hair 
cells of the mammalian inner ear. Neuron. 
2013;79(3):504–515.
 41. Kim KX, Beurg M, Hackney CM, Furness DN, 
Mahendrasingam S, Fettiplace R. The role of 
transmembrane channel-like proteins in the 
operation of hair cell mechanotransducer chan-
nels. J Gen Physiol. 2013;142(5):493–505.
 42. Beurg M, Kim KX, Fettiplace R. Conductance and 
block of hair-cell mechanotransducer channels 
in transmembrane channel-like protein mutants. 
J Gen Physiol. 2014;144(1):55–69.
 43. Sha SH, Schacht J. Stimulation of free radical for-
mation by aminoglycoside antibiotics. Hear Res. 
1999;128(1–2):112–118.
 44. Fischel-Ghodsian N, et al. Mitochondrial gene 
mutation is a significant predisposing factor in 
aminoglycoside ototoxicity. Am J Otolaryngol. 
1997;18(3):173–178.
 45. Esterberg R, Hailey DW, Coffin AB, Raible DW, 
Rubel EW. Disruption of intracellular calcium 
regulation is integral to aminoglycoside-induced 
hair cell death. J Neurosci. 2013;33(17):7513–7525.
 46. Francis SP, et al. A novel role of cytosolic protein 
synthesis inhibition in aminoglycoside ototoxic-
ity. J Neurosci. 2013;33(7):3079–3093.
 47. Pacifici GM. Clinical pharmacokinetics of amino-
glycosides in the neonate: a review. Eur J Clin 
Pharmacol. 2009;65(4):419–427.
 48. Durante-Mangoni E, Grammatikos A, Utili R, Fal-
agas ME. Do we still need the aminoglycosides? 
Int J Antimicrob Agents. 2009;33(3):201–205.
 49. Akshay S, et al. Phylogenetic sequence variations 
in bacterial rRNA affect species-specific suscep-
tibility to drugs targeting protein synthesis. Anti-
microb Agents Chemother. 2011;55(9):4096–4102.
 50. Wilson DN, Harms JM, Nierhaus KH, Schlunzen 
F, Fucini P. Species-specific antibiotic-ribosome 
interactions: implications for drug development. 
Biol Chem. 2005;386(12):1239–1252.
 51. Minor LB, Schessel DA, Carey JP. Meniere’s dis-
ease. Curr Opin Neurol. 2004;17(1):9–16.
 52. Wuts PGM, Greene TW. Greene’s Protective 
Groups in Organic Synthesis. 5th ed. Hoboken, 
New Jersey, USA: John Wiley & Sons; 2014.
 53. Peng AW, Effertz T, Ricci AJ. Adaptation of 
mammalian auditory hair cell mechanotrans-
duction is independent of calcium entry. Neuron. 
2013;80(4):960–972.
 54. [No authors listed]. A guide to sensitivity testing. 
Report of the Working Party on Antibiotic Sen-
sitivity Testing of the British Society for Antimi-
crobial Chemotherapy. J Antimicrob Chemother. 
1991;27(suppl D):1–50.
 55. Xia A, Visosky AM, Cho JH, Tsai MJ, Pereira FA, 
Oghalai JS. Altered traveling wave propagation and 
reduced endocochlear potential associated with 
cochlear dysplasia in the β2/NeuroD1 null mouse.  
J Assoc Res Otolaryngol. 2007;8(4):447–463.
 56. Cho SI, et al. Mechanisms of hearing loss after 
blast injury to the ear. PLoS One. 2013;8(7):e67618.
Downloaded from http://www.jci.org on April  1, 2015.   http://dx.doi.org/10.1172/JCI77424
